Search research articles
Contact Us
Filters
Showing results (91-100 of 99) with videos related to
Page
of 10
Sort By:
You have reached the last page of results.
This site can display upto 99 results.
JAMA
|
July 17, 2023
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial
John R Sims, Jennifer A Zimmer, Cynthia D Evans, et al.
The Journal of Prevention of Alzheimer'S Disease
|
December 2, 2025
Donanemab in early symptomatic Alzheimer's disease: results from the TRAILBLAZER-ALZ 2 long-term extension
Jennifer A Zimmer, John R Sims, Cynthia D Evans, et al.
JAMA Neurology
|
March 10, 2025
Amyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer Disease: Secondary Analysis of the TRAILBLAZER-ALZ and ALZ 2 Randomized Clinical Trials
Jennifer A Zimmer, Paul Ardayfio, Hong Wang, et al.
JAMA Neurology
|
November 26, 2019
Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease: The AMARANTH and DAYBREAK-ALZ Randomized Clinical Trials
Alette M Wessels, Pierre N Tariot, Jennifer A Zimmer, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
September 25, 2024
MEDI1814 selectively reduces free Aβ42 in cerebrospinal fluid of non-clinical species and Alzheimer's disease patients
Christopher Lloyd, Per-Ola Freskgård, Philip Newton, et al.
Nature Medicine
|
March 4, 2020
Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration
Elisabeth H Thijssen, Renaud La Joie, Amy Wolf, et al.
Neurology
|
September 26, 2012
Vascular neurologists and neurointerventionalists on endovascular stroke care: polling results
Thanh N Nguyen, Osama O Zaidat, Randall C Edgell, et al.
JAMA Neurology
|
April 29, 2024
Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial
Olivia Wagemann, Haiyan Liu, Guoqiao Wang, et al.
Nature Medicine
|
June 22, 2021
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease
Stephen Salloway, Martin Farlow, Eric McDade, et al.
Page
of 10
Search research articles
Search
Showing results (91-100 of 99) with videos related to
Sort By:
Page
of 10
You have reached the last page of results.
This site can display upto 99 results.
JAMA
|
July 17, 2023
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial
John R Sims, Jennifer A Zimmer, Cynthia D Evans, et al.
The Journal of Prevention of Alzheimer'S Disease
|
December 2, 2025
Donanemab in early symptomatic Alzheimer's disease: results from the TRAILBLAZER-ALZ 2 long-term extension
Jennifer A Zimmer, John R Sims, Cynthia D Evans, et al.
JAMA Neurology
|
March 10, 2025
Amyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer Disease: Secondary Analysis of the TRAILBLAZER-ALZ and ALZ 2 Randomized Clinical Trials
Jennifer A Zimmer, Paul Ardayfio, Hong Wang, et al.
JAMA Neurology
|
November 26, 2019
Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease: The AMARANTH and DAYBREAK-ALZ Randomized Clinical Trials
Alette M Wessels, Pierre N Tariot, Jennifer A Zimmer, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
September 25, 2024
MEDI1814 selectively reduces free Aβ42 in cerebrospinal fluid of non-clinical species and Alzheimer's disease patients
Christopher Lloyd, Per-Ola Freskgård, Philip Newton, et al.
Nature Medicine
|
March 4, 2020
Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration
Elisabeth H Thijssen, Renaud La Joie, Amy Wolf, et al.
Neurology
|
September 26, 2012
Vascular neurologists and neurointerventionalists on endovascular stroke care: polling results
Thanh N Nguyen, Osama O Zaidat, Randall C Edgell, et al.
JAMA Neurology
|
April 29, 2024
Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial
Olivia Wagemann, Haiyan Liu, Guoqiao Wang, et al.
Nature Medicine
|
June 22, 2021
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease
Stephen Salloway, Martin Farlow, Eric McDade, et al.
Page
of 10